期刊文献+

新型Rho激酶抑制剂DL08052的一般药理学研究 被引量:2

General pharmacology of the new Rho kinase inhibitor DL0805-2
原文传递
导出
摘要 目的:新结构Rho激酶抑制剂DL0805-2是前期发现的抗高血压急症候选药物,实验拟观察DL0805-2对心血管系统、呼吸系统和中枢神经系统的影响。方法:将SD大鼠30只随机分成DL0805-2低、中、高剂量组(3,10和30 mg·kg-1)、法舒地尔(fasudil)对照组和空白对照组,观察DL0805-2对大鼠心血管系统和呼吸系统的影响。将ICR种小鼠30只随机分组同前,按体表面积换算成相应剂量,观察DL0805-2对小鼠中枢神经系统的作用。结果:DL0805-2对心率、心电、心功能、呼吸频率和幅度、自主活动和爬杆能力无明显影响,对血压有一定的降低作用。结论:DL0805-2对中枢神经系统、呼吸系统和心功能均无明显影响,对血压有短暂的降低作用。DL0805-2不良反应较小,值得进一步研究和开发。 Objective: To investigate the effects of DL0805-2 on cardiovascular, respiratory, and nervous systems. Methods: Thirty Sprague-Dawley rats were equally randomized into five groups: three groups of DL0805- 2 (3, 10, 30 rag- kg- 1 ) , fasudil group ( 10 rag. kg-~ ) and solvent control group. The effects of DL0805-2 on car- diovascular and respiratory systems were observed. Thirty ICR mice were equally randomized into five groups as a- bove. The dose was converted according to the body surface area, and the effects of DL0805-2 on central nervous systems were observed. Results: DL0805-2 had no significant effect on heart rate, ECG, heart function, respirato- ry frequency and amplitude, locomotor activity and ability of climbing pole, but could decrease blood pressure. Conclusion: DL0805-2 has no significant effect on the central nervous system, respiratory system and heart func- tion in spite of temporary decreasing the blood pressure. Therefore, the side effect of DL0805-2 is small; it is wor- thy of further research and development, and clinical application.
出处 《中国新药杂志》 CAS CSCD 北大核心 2015年第18期2065-2072,共8页 Chinese Journal of New Drugs
基金 国家“重大新药创制”科技重大专项(2013ZX09103001-008,2012ZX09103101-078,2013ZX09508104)
关键词 DL0805-2 一般药理学 RHO激酶抑制剂 法舒地尔 超声心动图 DL0805-2 general pharmacology Rho kinase inhibitor fasudil echocardiogram
  • 相关文献

参考文献10

  • 1SADOK A, MARSHALL CJ. Rho GTPases: masters of cen mi- gration[ J]. Small GTPases, 2014, 5 :e29710.
  • 2JULIAN L, OLSON MF. Rho-associated coiled-coil containing kinases (ROCK) : structure, regulation, and functions [ J ~. Small GTPases, 2014, 5 (2) : e29846.
  • 3TSOUNAPI P, SAITO M, KITATANI K, et al. Fasudil improves the endothelial dysfunction in the aorta of spontaneously hypertensire rats[ J]. Eur J Pharmacol, 2012, 691 ( 1 -3) : 182 - 189.
  • 4武玉洁,王夙博,袁天翊,李人则,焦晓臻,谢平,方莲花,杜冠华.新型Rho激酶抑制剂DL0805-1大鼠体内药代动力学初步研究[J].中国药理学通报,2014,30(8):1171-1174. 被引量:3
  • 5YUAN TY, YAN Y, WU Y J, et al. Vasodilatory effect of a novel Rho-kinase inhibitor, DL0805-2, on the rat mesenteric artery and its potential mechanisms[ J]. Carcliovasc Drugs Ther, 2014, 28 (5) : 415 -424.
  • 6钱伯初,史红.试论安全药理学研究的基本要求及规范化[J].中国新药杂志,2006,15(7):491-494. 被引量:5
  • 7王玉珠,王庆利.从监管角度看支持新药开展临床试验的安全药理学研究的重要意义[J].中国新药杂志,2012,21(7):718-721. 被引量:2
  • 8FAVA A, WUNG PK, WIGLEY FM, et al. Efficacy of Rho ki- nase inhibitor fasudil in secondary Raynaud's phenomenon [ J ]. Arthritis Care Res, (Hoboken), 2012, 64(6) : 925 -929.
  • 9XIAO JW, ZHU XY, WANG QG, et al. Acute effects of Rho-ki- nase inhibitor fasudil on pulmonary arterial hypertension in pa- tients with congenital heart defects [ J]. Circ J, 2015,79 ( 6 ) : 1342 - 1348.
  • 10ZHANG Q, ZHANG JJ, HAN ZM. Efficacy of Rho kinase inhib- itor on cognitive impairment induced by chronic cerebral hypoper- fusion in rats[J]. lnt J Clin Exp Med, 2015, 8(2) : 2435 - 2440.

二级参考文献24

共引文献7

同被引文献10

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部